Is Ketamine Legal in the US? Federal Status, Prescriptions, and Clinical Use
Ketamine is federally legal in the US as a Schedule III controlled substance, available by prescription for approved uses. Off-label prescribing is widespread, but only some forms are FDA-approved for specific conditions.
Is Ketamine Legal in the United States?
Yes, ketamine is federally legal in the United States—but only under specific conditions. Ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act (CSA), meaning it is legal to possess and use with a valid prescription from a licensed healthcare provider. Without a prescription, possession or distribution is illegal and subject to criminal penalties. This article is for informational purposes only and does not constitute legal advice.
Federal Scheduling and Legal Framework
Ketamine's legal status is defined by its placement in Schedule III of the CSA, which covers substances with moderate to low potential for physical and psychological dependence. Schedule III drugs are recognized as having accepted medical uses in the US, but remain regulated due to their abuse potential. The Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) oversee its legal use and distribution.
Ketamine was originally approved by the FDA in 1970 as a dissociative anesthetic for use in humans and animals. Its medical uses have since expanded, but its status as a controlled substance means it is subject to strict prescribing, storage, and recordkeeping requirements. For more on the regulatory landscape, see our psychedelic law explainer.
FDA Approvals: What Is Allowed?
The FDA has approved ketamine for anesthesia and pain management. In 2019, the FDA also approved Spravato (esketamine nasal spray), a derivative of ketamine, for treatment-resistant depression. However, Spravato is not the same as generic ketamine:
- Spravato (esketamine) is FDA-approved for adults with treatment-resistant depression and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. It must be administered in a certified healthcare setting under a Risk Evaluation and Mitigation Strategy (REMS) program, requiring in-office observation after dosing.
- IV and IM ketamine (intravenous and intramuscular) are not FDA-approved for depression, PTSD, or other psychiatric indications. However, physicians may prescribe ketamine "off-label" for these conditions, meaning they use their medical judgment to prescribe it outside of its FDA-approved indications.
For a comprehensive overview of the research landscape, visit our psychedelic research landscape page.
Off-Label Use: Common Practice, Not Officially Approved
Off-label prescribing is legal and common in US medicine, especially in psychiatry. Many clinics and providers offer ketamine infusions for depression, anxiety, PTSD, and chronic pain. While this is not FDA-approved, it is not prohibited as long as the provider is licensed and follows applicable state and federal laws. Patients should be aware that:
- Insurance coverage for off-label ketamine is rare.
- Safety and efficacy for off-label uses are still under investigation.
- Providers must comply with DEA regulations for storage, recordkeeping, and prescribing.
For more on off-label use and clinical research, see our guides and briefing feed.
State Laws and Local Variations
While federal law sets the baseline, states may impose additional restrictions or requirements on ketamine prescribing and administration. Some states have more stringent rules regarding controlled substances, telemedicine, or clinic certification. However, there are no states where ketamine is legal without a prescription, nor are there states where it is fully decriminalized for non-medical use.
Clinics and providers must comply with both federal and state law. Patients considering ketamine treatment should verify the credentials of their provider and ensure the clinic operates legally. For more on navigating legal risks and compliance, see our psychedelic law resource.
Ketamine in the Broader Psychedelic Landscape
Ketamine occupies a unique position in the US psychedelic landscape. Unlike classic psychedelics such as psilocybin or MDMA, which remain Schedule I substances federally, ketamine is already available for medical use. This has made it the most widely accessible "psychedelic-adjacent" therapy in the US, with hundreds of clinics offering treatments for mental health conditions.
Recent regulatory shifts—such as the FDA's approval of MDMA for PTSD—may influence future policy on ketamine and other psychedelics. However, at present, ketamine's legal status remains distinct and is governed by its Schedule III classification and FDA-approved indications. For more on the evolving field, see our research landscape and briefing pages.
What Should Patients, Providers, and Researchers Do Next?
If you are considering ketamine treatment, consult with a licensed healthcare provider who is experienced in its use. Ensure the clinic follows all legal and safety protocols. For providers and researchers, staying updated on federal and state regulations is essential, especially as the field evolves. For a comprehensive guide to current laws, clinical best practices, and research, visit our pillar guide and legal resources.